ColoAlert® Revenue Increases 102% Year Over Year for the Nine Months Ended September 30, 2023ColoFuture Study Reported Groundbreaking Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 80%
More here:
Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update
CORAL GABLES, Fla., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the management team, will participate at the upcoming Piper Sandler 35th Annual Healthcare Conference taking place at the Lotte New York Palace hotel.
See more here:
Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference
Apollomics’ partner, Avistone Biotechnology, received approval from Chinese National Medical Products Administration (NMPA) to commercialize vebreltinib (APL-101) in China
PITTSBURGH, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a human biomaterials company (“Carmell”), today announced the addition of two independent directors to their Board.
Read more here:
Carmell Corp Announces Addition of Scott Frisch and Gilles Spenlehauer to Board of Directors
GRANT, N.M., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Bright Green Corporation (BGXX) (“BGXX”, “Bright Green” or the “Company”) today announced the Company’s new alliance with Asia Capital Pioneers Group Inc. (“ACPG”), an Asia-based investment firm with global investments within high growth industries. ACPG will be BGXX’s exclusive Asia partner, connecting the Company with investors that fulfill the requirements for permanent U.S. residency via an EB-5 Investment Visa in the Asia-Pacific region.
Read the rest here:
Bright Green Corporation announces exclusive partnership with Asia Capital Pioneers Group to present new EB-5 offering
BMF-219 is an investigational novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure diabetes BMF-219 is an investigational novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure diabetes
Dr. Benz, former president and chief executive officer of Dana-Farber Cancer Institute, joins CoRegen's Board of Directors, bringing more than three decades of expertise in oncology research and cancer care Dr. Benz, former president and chief executive officer of Dana-Farber Cancer Institute, joins CoRegen's Board of Directors, bringing more than three decades of expertise in oncology research and cancer care
Continue reading here:
CoRegen Appoints Edward J. Benz, M.D., to its Board of Directors
FREMONT, CA, Nov. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that it entered into a global licensing definitive agreement with AiBtl BioPharma Inc. (AiBtl) for the Company's CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (the "Licensed Products"). The agreement has the potential of licensing income worth $467M and royalties up to $200M.
Follow this link:
ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M
Leuven, BELGIUM, Boston, MA, US – November 16, 2023 – 7 pm CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced today that it has received EUR 1.0 million in funding under the Subscription Agreement with Atlas Special Opportunities LLC (“Atlas”).
SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 2,000,000 shares of the Company’s common stock at a purchase price of $0.65 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about November 20, 2023, subject to the satisfaction of customary closing conditions.